Breakthrough Business Solutions to Advance Personalized or Precision Medicine

05 August 2016 Personalized Medicine Bulletin Blog
Authors: Antoinette F. Konski

In today’s era of unprecedented opportunities and complexity within personalized medicine, it has become critical innovators in the space to adopt a collaborative approach with outside experts in order to quickly and affordably bring new products and services to market. And, as it turns out, collaboration may also be the key to achieving mainstream clinical adoption.

Hosted by Foley & Lardner LLP and the Personalized Medicine Coalition, the 4th Annual Business of Personalized Medicine Summit will examine in depth the financial, regulatory, policy, R&D, and technology-related complexities, trends, and opportunities impacting the marketplace and the future of health care by highlighting some of the innovative partnering and collaboration taking place throughout the industry. Join top executives from across multiple stakeholder perspectives to explore strategies for capitalizing on this challenging yet profitable market, plus solutions for advancing the field.

OPENING KEYNOTE

Margaret Anderson, Executive Director, FasterCures, a Center of the Milken Institute

Margaret Anderson is the executive director of FasterCures, a Washington DC-based center of the Milken Institute, which is driven by a singular goal – to save lives by speeding up and improving the medical research system. FasterCures focuses on spurring cross-sector collaboration, cultivating a culture of innovation and engaging patients as partners. Anderson is also acting president and CEO of the Melanoma Research Alliance, the largest private funder of melanoma research, and served as secretary of the board for years before taking on her recent leadership role. She is a founding board member and past-president of the Alliance for a Stronger FDA, is a member of the NIH National Center for Advancing Translational Sciences Advisory Council and Cures Acceleration Network Review Board, the National Health Council board, United for Medical Research Steering Committee, the Food and Drug Administration’s Science Board, Science Looking Forward Committee and the Institute of Medicine’s Forum on Drug Discovery, Development and Translation.

CLOSING KEYNOTE

Jonathan Hirsch, President & Founder, Syapse

Jonathan Hirsch is the Founder and President of Syapse, a software company transforming health care by bringing omics into routine medical use. At Syapse, Jonathan works closely with diagnostic and health care providers, helping translate customer problems into software solutions. Jonathan is an Advisory Board member of the SXSW Accelerator, a mentor for UCSF Lean Launchpad for Healthcare course, and a member of the Steering Committee of Free the Data!, an effort started by Genetic Alliance to crowdsource the interpretation of cancer genes.

FEATURED TOPICS

  • Understanding digital health solutions as personalized medicine products
  • Anatomy of a venture capital investment
  • Reimbursement trends and changes in payment policy
  • Models for data collection and sharing
  • Innovative next-generation sequencing technologies and applications
  • Regulation and use of biomarkers in drug discovery and clinical practice
  • Clinical adoption challenges and solutions from international pharma and provider perspectives

REGISTER TODAY

For a complete conference schedule, list of confirmed speakers, and registration details, visit www.personalizedmedicinesummit.com.

See you in September !

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.

Related Services